POAI (Predictive Oncology) שולי הרווח הגולמי

Geopolitical risks and data exchange restrictions are hindering the expansion of Predictive Oncology (POAI). The net gross margin reflects current dynamics, with the value fixed at -19.30. The business relies on AI-driven modeling of tumor responses and the volume of clinical databases. High retention is ensured by integration into the R&D of pharma behemoths and support from the FDA regarding preclinical testing.
פילוחים אנליטיים ודוחות נתונים של חברת Predictive Oncology Inc. (POAI)

Gross margin determines capital resilience to market shocks by measuring the share of profit after deducting direct production costs. The high technological barrier of Predictive Oncology (POAI), driven by proprietary algorithms and unique biodata, creates a foundation for high profitability, which is reflected in the gross income metric, helping investors assess the efficiency of intellectual property monetization and the risk of overpaying for the asset.